Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma

被引:109
作者
Fassas, ABT [1 ]
Spencer, T [1 ]
Sawyer, J [1 ]
Zangari, M [1 ]
Lee, CK [1 ]
Anaissie, E [1 ]
Muwalla, F [1 ]
Morris, C [1 ]
Barlogie, B [1 ]
Tricot, G [1 ]
机构
[1] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA
关键词
hypodiploidy; deletion chromosome 13; prognosis; multiple myeloma;
D O I
10.1046/j.1365-2141.2002.03757.x
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Complete or partial deletion of chromosome 13 or translocations involving 13q (Delta13) by conventional cytogenetic analysis confers a poor prognosis in multiple myeloma (MM) patients, even with timely application of tandem autologous transplants. It was recently suggested that the prognostic significance of Delta13 is related to its frequent association with hypodiploidy but by itself does not have a poor prognostic significance. We therefore analysed our experience in 1475 consecutive MM patients in whom we intended treatment with tandem transplants after a melphalan-based conditioning regimen. Patients with abnormal cytogenetic analysis were grouped into hypodiploid/hypotetraploid, pseudodiploid and hyperdiploid groups, according to their modal chromosome number. Their event-free and overall survival were compared with those of patients with a normalkaryotype. Both hypodiploidy and Delta13 were found to independently confer poor prognosis in MM patients. Furthermore, these parameters in combination with easily obtained pretransplant levels of beta-2 microglobulin and albumin define three groups of MM patients with clearly distinct outcomes.
引用
收藏
页码:1041 / 1047
页数:7
相关论文
共 39 条
[1]
High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions [J].
Badros, A ;
Barlogie, B ;
Morris, C ;
Desikan, R ;
Martin, SR ;
Munshi, N ;
Zangari, M ;
Toor, A ;
Cottler-Fox, M ;
Fassas, A ;
Aniassie, E ;
Schichman, S ;
Tricot, G .
BLOOD, 2001, 97 (09) :2574-2579
[2]
Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma [J].
Barlogie, B ;
Jagannath, S ;
Vesole, DH ;
Naucke, S ;
Cheson, B ;
Mattox, S ;
Bracy, D ;
Salmon, S ;
Jacobson, J ;
Crowley, J ;
Tricot, G .
BLOOD, 1997, 89 (03) :789-793
[3]
BARLOGIE B, 1989, BLOOD, V73, P865
[4]
BARLOGIE B, 1985, BLOOD, V66, P338
[5]
Bueno PR, 1998, HEAD NECK-J SCI SPEC, V20, P232, DOI 10.1002/(SICI)1097-0347(199805)20:3<232::AID-HED8>3.0.CO
[6]
2-1
[7]
Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma [J].
Calasanz, MJ ;
Cigudosa, JC ;
Odero, MD ;
GarciaFoncillas, J ;
Marin, J ;
Ardanaz, MT ;
Rocha, E ;
Gullon, A .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 98 (02) :418-425
[8]
The use of biological variables to predict outcome in multiple myeloma [J].
Davies, FE ;
Jack, AS ;
Morgan, GJ .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 99 (04) :719-725
[9]
Desikan R, 2000, BLOOD, V95, P4008
[10]
DEWALD GW, 1985, BLOOD, V66, P380